Table 4.
Statin type and the risk of pneumonia requiring hospitalization within a 90-day exposure
| Controls | Cases | Crude OR | Adjusteda OR | |||
|---|---|---|---|---|---|---|
| N | N | (95 % CI) | P | (95 % CI) | P | |
| Overall MI patients | 4,778 | 963 | - | - | ||
| Statin type | ||||||
| Artovastatin | 3,242 | 639 | 1.00 (Ref.) | 1.00 (Ref.) | ||
| Fluvastatin | 556 | 132 | 1.21 (0.94–1.56) | 0.136 | 1.14 (0.85–1.52) | 0.390 |
| Simvastatin | 510 | 109 | 1.04 (0.79–1.38) | 0.781 | 1.19 (0.87–1.64) | 0.283 |
| Other | 470 | 83 | 0.87 (0.65–1.17) | 0.363 | 0.73 (0.51–1.03) | 0.075 |
| MI patients unexposed to statin pretreatment | 2,683 | 403 | ||||
| Statin type | ||||||
| Atorvastatin | 1,863 | 270 | 1.00 (Ref.) | 1.00 (Ref.) | ||
| Fluvastatin | 297 | 55 | 1.16 (0.71–1.90) | 0.549 | 1.11 (0.6–2.04) | 0.743 |
| Simvastatin | 278 | 54 | 0.80 (0.49–1.32) | 0.386 | 1.12 (0.59–2.10) | 0.729 |
| Other | 245 | 24 | 0.65 (0.36–1.17) | 0.153 | 0.66 (0.31–1.41) | 0.286 |
ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS 2 congestive heart failure, hypertension, age > 75 years, diabetes, previous stroke, CI confidence interval; COPD, chronic obstructive pulmonary disease, DDD defined daily dose, DDD 90 average defined daily dose within 90 days, OR odds ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
a Adjusted for CHASD2 score, medical conditions (diabetes mellitus, hypertension, chronic heart failure, stroke, COPD, chronic kidney disease, chronic liver disease, Parkinson disease, and dementia) and medication use (antineoplastic drug, PPI, ACEI/ARB, antiviral drug, immunosuppressants, immunostimulants, nitrate, antiplatelet and influenza or pneumococcal vaccine)